

Pharmacy Formulary Updates for June 2021

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in June 2021:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Gemtesa (vibegron)	Tier 3, STPA (Step 3) (Overactive Bladder Medications Step Therapy program)
Cosela (trilaciclib)	MB, PA
Tepmetko (tepotinib)	Tier 2; PA
Ukoniq (umbralisib)	Tier 2; PA
Margenza (margetuximab)	MB
Bronchitol (mannitol)	Tier 3; PA; QL; (560 capsules per 28 days; 20 per day)
Vesicare LS (solifenacin succinate) suspension)	Tier 3, STPA, Step 2 (Overactive Bladder Medications Step Therapy program)
Hetlioz (tasimelteon) oral suspension	Tier 3, PA, QL (158mL bottle: 1 bottle/30 days and 48mL bottle: 3 bottles/30 days)
Chloroquine tablets (brand/generic)	Tier 1
hydroxychloroquine (generic)	Tier 1
Plaquenil (brand)	Tier 3
Xolair prefilled syringes (Brand)	Tier 2, PA, SP, QL (8 prefilled syringes per 28 days)
Coartem (Brand)	Tier 2; QL 24 tablets/90 days

Key:

- | | |
|--------------------------------|--|
| MB: Medical Benefit | QL: Quantity Limitation |
| NC: Not covered | SP: Specialty Pharmacy - provided through CVS/specialty |
| NTM: New-to-market | ST: Step Therapy |
| PA: Prior Authorization | |